A review of the mechanisms underlying selected comorbidities in Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 175 of the 176 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder of the central nervous system (CNS) leading to mental deterioration and devastation, and eventually a fatal outcome. AD affects mostly the elderly. AD is frequently accompanied by hypercholesterolemia, hypertension, atherosclerosis, and diabetes mellitus, and these are significant risk factors of AD. Other conditions triggered by the progression of AD include psychosis, sleep disorders, epilepsy, and depression. One important comorbidity is Down’s syndrome, which directly contributes to the severity and rapid progression of AD. The development of new therapeutic strategies for AD includes the repurposing of drugs currently used for the treatment of comorbidities. A better understanding of the influence of comorbidities on the pathogenesis of AD, and the medications used in its treatment, might allow better control of disease progression, and more effective pharmacotherapy. Graphic abstract
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Insulin resistance can lead to a disruption in glucose transport and then to weakened glucose metabolism; together, they are thought to cause neurodegeneration in AD [85].”
From Primary Cilia and Cardiovascular Risk Factors in Alzheimer's Disease (2025) · cites this paper as [85]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Global estimates of diabetes prevalence for 2013 and projections for 2035
Guariguata, L., Whiting, D. R., Hambleton, I., Beagley, J., Linnenkamp, U., & Shaw, J. E. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.11.002 · Cited by 4,642
Danbolt, N. C. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00067-8 · Cited by 4,227
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
(2015) · HAL · Cited by 2,238
World Alzheimer Report 2018: The state of the art of dementia research: New frontiers
Patterson, C. (2018) · Cited by 1,461
Role of Glutamate and NMDA Receptors in Alzheimer’s Disease
Wang, R., & Reddy, P. H. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160763 · Cited by 1,009
Research works printed but not linked: 1
- Lawlor B, Segurado R, Kennelly S, Rikkert M, Howard R, Pasquier F, et al. Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial. PLoS Med. 2018;15(9):20. · DOI · Paper page
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“Currently, antibodies like aducanumab ( 1 ), lecanemab ( 2 ), and donanemab ( 10 ) show their promise in proving A β as a signi fi cant factor in AD development.”
BackgroundStress-Induced Depression and Alzheimer’s Disease: Focus on Astrocytes
Dolotov, O. V., Inozemtseva, L. S., Myasoedov, N. F., & Grivennikov, I. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094999 · Cited by 109
“It is assumed that the desensitization of GR is an important cause of both HPAA deregulation and activation of the immune system [37,41], although there is no correlation between inflammation and glucocorticoid resistance in patients [54].”
BackgroundAlzheimer’s Disease: A Brief History of Immunotherapies Targeting Amyloid β
Vogt, A.-C. S., Jennings, G. T., Mohsen, M. O., Vogel, M., & Bachmann, M. F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043895 · Cited by 84
“The effects of comorbidities are particularly important in AD patients as most of them have at least one comorbid condition [17].”
BackgroundAdewuyi, E. O., O’Brien, E. K., Nyholt, D. R., Porter, T., & Laws, S. M. (2022) · Communications Biology · doi:10.1038/s42003-022-03607-2 · Cited by 83
AbouElhassan, K. M., Sarhan, H. A., Hussein, A. K., Taye, A., Ahmed, Y. M., & Safwat, M. A. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s381353 · Cited by 45
“Acetylcholine (ACh) is the primary cholinergic neurotransmitter synthesis in the central neurons responsible for maintaining consciousness, recognition, thinking, and learning, especially in the basal forebrain, frontal lobe, hippocampus, and brainstem.(14,15) Decreased Ach levels in the brain significantly characteri…”
Background
Metadata
- Authors
- Maciejewska, K., Czarnecka, K., & Szymański, P.
- Affiliations
- Medical University of Lodz (PL)
- Corresponding author
- Szymański, Paweł
- Venue
- Pharmacological Reports
- Published
- 2021-06-13
- Volume
- 73
- Issue
- 6
- Pages
- 1565-1581
- ISSN
- 1734-1140 (ISSN-L)
- 2299-5684
- PMC
- PMC8599320
- OpenAlex
- W3171782439
- Cited by
- 64
- References
- 176
- Citations by year
- 2026: 12 · 2025: 17 · 2024: 11 · 2023: 10 · 2022: 12 · 2021: 2
- FWCI
- 1.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Pharmacological Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Narodowym Centrum Nauki (2015/19/B/NZ7/02847)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, comorbidities, hypercholesterolemia, hypertension, atherosclerosis, diabetes mellitus, psychosis, sleep disorders, epilepsy, depression, Down syndrome, drug repurposing, pharmacotherapy, pathogenesis
- MeSH terms
- Drug Development, Aged, Alzheimer Disease, Animals, Humans, Risk Factors, Disease Progression, Drug Repositioning, Patient Acuity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A review of the mechanisms underlying selected comorbidities in Alzheimer’s disease. https://app.cochat.ai/papers/10.1007/s43440-021-00293-5
- The paper
- Maciejewska, K., Czarnecka, K., & Szymański, P. (2021). A review of the mechanisms underlying selected comorbidities in Alzheimer’s disease. Pharmacological Reports. https://doi.org/10.1007/s43440-021-00293-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
